Copper/Cholesterol Interaction in Alzheimer's Disease

Principal Investigator
Ashley Bush, MD, PhD
Mental Health Research Institute
Parkville, Victoria, Australia
About the Research Project
Program
Award Type
Standard
Award Amount
$300,000
Active Dates
April 01, 2005 - March 31, 2007
Grant ID
A2005091
Summary
In Alzheimer’s disease a normal protein called beta-amyloid (Aβ) has been found to accumulate abnormally in the brain. AD has also been associated with abnormalities in cholesterol metabolism. Both links, however, are complex and the results of their specific effects have not yet been pin-pointed. Dr. Bush’s team has discovered Aβ to be a copper binding protein. Copper (like cholesterol) is a normally abundant part of brain chemistry, but in AD Aβ abnormally utilizes copper’s chemical energy to convert cholesterol into hydrogen peroxide. This is a damaging reaction that may be the cause of the toxicity of Aβ. Through a five part research analysis, Dr. Bush’s studies will help illuminate the complex biochemistry of Aβ in its reactions with copper and cholesterol in the brain.
Related Grants
Alzheimer's Disease Research
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027
Principal Investigator
Frances Wiseman, PhD
Current Organization
University College London (UK)
The Role of DYRK1A in Altered Microglia Biology in a Cellular Model of Alzheimer’s Disease in Down Syndrome
Active Dates
January 01, 2025 - December 31, 2027

Principal Investigator
Frances Wiseman, PhD
Current Organization
University College London (UK)
Alzheimer's Disease Research
Defining the Impact of Cytokine Signaling in Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Dong Kyu Kim, PhD
Current Organization
University of California
Defining the Impact of Cytokine Signaling in Alzheimer’s Disease
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Dong Kyu Kim, PhD
Current Organization
University of California
Alzheimer's Disease Research
Decoding Alzheimer’s Disease Genomes With Deep Learning
Active Dates
July 01, 2024 - June 30, 2026
Principal Investigator
Tatsuhiko Naito, MD, PhD
Current Organization
Icahn School of Medicine at Mount Sinai
Decoding Alzheimer’s Disease Genomes With Deep Learning
Active Dates
July 01, 2024 - June 30, 2026

Principal Investigator
Tatsuhiko Naito, MD, PhD
Current Organization
Icahn School of Medicine at Mount Sinai